Detalhe da pesquisa
1.
Sitravatinib combined with PD-1 blockade enhances cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma.
Carcinogenesis;
45(4): 210-219, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38019590
2.
Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.
J Transl Med;
22(1): 402, 2024 Apr 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38689325
3.
CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.
Carcinogenesis;
43(9): 842-850, 2022 10 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35552655
4.
A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study.
Mol Cancer;
21(1): 44, 2022 02 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35148754
5.
A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma.
Br J Cancer;
127(11): 2016-2024, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36097175
6.
Measurement of outflow resistance imposed by magnetic sphincter augmentation: defining normal values and clinical implication.
Surg Endosc;
35(10): 5787-5795, 2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33051761
7.
Magnetic sphincter augmentation (MSA) in patients with hiatal hernia: clinical outcome and patterns of recurrence.
Surg Endosc;
34(4): 1835-1846, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31286251
8.
Comparison of surgical payer costs and implication on the healthcare expenses between laparoscopic magnetic sphincter augmentation (MSA) and laparoscopic Nissen fundoplication (LNF) in a large healthcare system.
Surg Endosc;
34(5): 2279-2286, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31376004
9.
The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
Ann Surg;
268(6): 992-999, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28806299
10.
Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.
Oncologist;
23(9): 1004-e102, 2018 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29769385
11.
Serial Endoscopic Evaluation of Esophageal Disease in a Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development.
Cancer Invest;
36(7): 363-370, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30142016
12.
Sep70/Pepsin expression in hypopharynx combined with hypopharyngeal multichannel intraluminal impedance increases diagnostic sensitivity of laryngopharyngeal reflux.
Surg Endosc;
32(5): 2434-2441, 2018 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29264754
13.
PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model.
Ann Surg;
266(1): 91-98, 2017 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27471841
14.
Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma.
Ann Surg;
264(2): 297-304, 2016 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26445473
15.
Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma.
BMC Cancer;
16: 52, 2016 Feb 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26841926
16.
A utility of peroral endoscopic myotomy (POEM) across the spectrum of esophageal motility disorders.
Surg Endosc;
30(1): 233-44, 2016 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25847137
17.
Hypopharyngeal pepsin and Sep70 as diagnostic markers of laryngopharyngeal reflux: preliminary study.
Surg Endosc;
29(5): 1080-7, 2015 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25159637
18.
Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma.
Cancer;
120(24): 3902-13, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25100294
19.
The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer.
Cancers (Basel);
16(2)2024 Jan 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38254776
20.
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.
Clin Cancer Res;
30(2): 389-403, 2024 01 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37939140